Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model
Masanobu Tsubaki1, Tomoya Takeda1, Toshiki Kino1
1Division of Pharmacotherapy, Kinki University School of Pharmacy Kowakae, Higashi-Osaka, Japan.
Abstract:
Metastatic melanoma is a life-threatening disease for which no effective treatment is currently available. In melanoma cells, Rho overexpression promotes invasion and metastasis. However, the effect of statins on spontaneous metastasis and tumor growth remains unclear. In the present study, we investigated the mechanism of statin-mediated tumor growth and metastasis inhibition in an in vivo model. We found that statins significantly inhibited spontaneous metastasis and tumor growth. Statins inhibited the mRNA expression and enzymatic activities of matrix metalloproteinases (MMPs) in vivo and also suppressed the mRNA and protein expression of very late antigens (VLAs). Moreover, statins inhibited the prenylation of Rho as well as the phosphorylation of LIM kinase, serum response factor (SRF), and c-Fos downstream of the Rho signaling pathway. In addition, statins enhanced p53, p21, and p27 expression and reduced phosphorylation of cyclin-dependent kinase and expression of cyclin D1 and E2. These results indicate that statins suppress Rho signaling pathways, thereby inhibiting tumor metastasis and growth. Furthermore, statins markedly improved the survival rate in a metastasis model, suggesting that statins have potential clinical applications for the treatment of metastatic cancers.
Insights
Statins effectively inhibit metastatic melanoma growth and spread by targeting the Rho signaling pathway. This research shows statins improve survival rates, indicating potential clinical use for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic melanoma is a deadly cancer with limited treatment options.
- Rho overexpression in melanoma cells drives invasion and metastasis.
- The impact of statins on melanoma metastasis and growth is not fully understood.
Purpose of the Study:
- To investigate the mechanism by which statins inhibit tumor growth and metastasis in vivo.
- To explore the effects of statins on Rho signaling pathways in melanoma.
Main Methods:
- Utilized an in vivo model to assess statin effects on spontaneous metastasis and tumor growth.
- Measured mRNA and protein expression of key molecules including MMPs, VLAs, Rho, and cell cycle regulators.
- Analyzed Rho prenylation and downstream signaling pathway phosphorylation (LIM kinase, SRF, c-Fos).
Main Results:
- Statins significantly reduced spontaneous metastasis and tumor growth.
- Inhibition of matrix metalloproteinases (MMPs) and very late antigens (VLAs) was observed.
- Statins suppressed Rho prenylation and downstream signaling, including LIM kinase, SRF, and c-Fos phosphorylation.
- Upregulation of p53, p21, and p27, with decreased cyclin-dependent kinase phosphorylation and cyclin D1/E2 expression.
Conclusions:
- Statins suppress Rho signaling pathways, effectively inhibiting melanoma metastasis and growth.
- Statins demonstrate potential clinical applications for treating metastatic cancers by improving survival rates.
